{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:54:29Z","timestamp":1787316869498,"version":"build-2736575974"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus (SLE), is driven by immune complex deposition and complement activation, resulting in glomerular inflammation and podocyte injury. Beyond being passive targets, podocytes actively modulate renal immunity through cytokine secretion and antigen presentation. Recent advances in urinary biomarkers such as NGAL, TWEAK, and MCP-1 and composite indices like the Renal Activity Index for Lupus (RAIL) offer dynamic and noninvasive monitoring of disease activity. Immunotherapy has transitioned from nonspecific immunosuppression to targeted biologics, with agents such as belimumab and telitacicept improving outcomes by modulating B-cell function. Additionally, emerging therapies including bortezomib and daratumumab demonstrate efficacy in refractory LN through plasma cell depletion. This review summarizes current immunological insights, biomarker innovations, and immunotherapy strategy to support precision medicine and improve long-term renal prognosis in LN.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1624850","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T04:22:15Z","timestamp":1759983735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Breaking the cycle: immune complexes, complement activation, and novel immunotherapies in lupus nephritis"],"prefix":"10.3389","volume":"16","author":[{"given":"Cuiting","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingda","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejiao","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.kint.2024.10.018","article-title":"Lupus nephritis: redefining the treatment goals","volume":"107","author":"De Vriese","year":"2025","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.3390\/ijms25116162","article-title":"Mitochondrial dysfunction in systemic lupus erythematosus with a focus on lupus nephritis","volume":"25","author":"Halfon","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/08916930903374774","article-title":"Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment","volume":"43","author":"Perl","year":"2010","journal-title":"Autoimmunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjnut.2025.06.031","article-title":"Protective role of dietary short-chain fatty acid propionate against autoimmune responses and pathology of systemic lupus erythematosus in MRL-lpr mice","volume":"155","author":"Wang","year":"2025","journal-title":"J Nutr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2174\/1573397116999201208213422","article-title":"Antineutrophil cytoplasmic antibody in lupus nephritis: correlation with clinicopathological characteristics and disease activity","volume":"17","author":"Said","year":"2021","journal-title":"Curr Rheumatol Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091340","article-title":"Podocyte injury in lupus nephritis","volume":"8","author":"Sakhi","year":"2019","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.159","article-title":"What is damaging the kidney in lupus nephritis","volume":"12","author":"Davidson","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012020133","article-title":"Podocytes are nonhematopoietic professional antigen-presenting cells","volume":"24","author":"Goldwich","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2400521","DOI":"10.1002\/smsc.202400521","article-title":"Targeting nanotherapeutics for highly efficient diagnosis and treatment of systemic lupus erythematosus through regulation of immune response","volume":"5","author":"Liu","year":"2025","journal-title":"Small Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmae015","article-title":"Noninvasive biomarkers for lupus nephritis","volume":"55","author":"Liu","year":"2024","journal-title":"Lab Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: A systematic review and bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead674","article-title":"The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis","volume":"64","author":"Chen","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: A review","volume":"331","author":"Siegel","year":"2024","journal-title":"Jama"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168981","article-title":"Lupus nephritis from pathogenesis to new therapies: an update","volume":"25","author":"Roveta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001104","article-title":"SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus","volume":"11","author":"Lee","year":"2024","journal-title":"Lupus Sci Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"175333","DOI":"10.1016\/j.scitotenv.2024.175333","article-title":"PM(2.5) constituents associated with mortality and kidney failure in childhood-onset lupus nephritis: A 19-year cohort study","volume":"949","author":"He","year":"2024","journal-title":"Sci Tot Environ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14809","article-title":"Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine","volume":"26","author":"Bhatnagar","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.trsl.2022.03.001","article-title":"CD11b agonists offer a novel approach for treating lupus nephritis","volume":"245","author":"Villanueva","year":"2022","journal-title":"Transl Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":":eadl3848","DOI":"10.1126\/scitranslmed.adl3848","article-title":"Lupus IgA1 autoantibodies synergize with IgG to enhance plasmacytoid dendritic cell responses to RNA-containing immune complexes","volume":"16","author":"Waterman","year":"2024","journal-title":"Sci Transl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"102900","DOI":"10.1016\/j.jaut.2022.102900","article-title":"Evidence for charge-based mimicry in anti dsDNA antibody generation","volume":"132","author":"Bruschi","year":"2022","journal-title":"J Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-010-8204-4","article-title":"Glomerular antibodies in lupus nephritis","volume":"40","author":"Hanrotel-Saliou","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0126564","DOI":"10.1371\/journal.pone.0126564","article-title":"Novel autoantigens associated with lupus nephritis","volume":"10","author":"Onishi","year":"2015","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02734","article-title":"Neutrophils-important communicators in systemic lupus erythematosus and antiphospholipid syndrome","volume":"10","author":"Wirestam","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e64650","DOI":"10.1371\/journal.pone.0064650","article-title":"Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis","volume":"8","author":"Gilkeson","year":"2013","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96492","article-title":"Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis","volume":"3","author":"Olaru","year":"2018","journal-title":"JCI Insight"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.09.006","article-title":"CD8+iTregs attenuate glomerular endothelial cell injury in lupus-prone mice through blocking the activation of p38 MAPK and NF-\u03baB","volume":"103","author":"Liu","year":"2018","journal-title":"Mol Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S473616","article-title":"Influence of podocyte injury on the development of class IV lupus nephritis","volume":"17","author":"Zago","year":"2024","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319828509","article-title":"The associations of endothelial and podocyte injury in proliferative lupus nephritis: from observational analysis to in vitro study","volume":"28","author":"Yuan","year":"2019","journal-title":"Lupus"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2019.08.011","article-title":"Lupus podocytopathy: an overview","volume":"26","author":"Oliva-Damaso","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313517152","article-title":"Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria","volume":"23","author":"Rezende","year":"2014","journal-title":"Lupus"},{"key":"B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.23876\/j.krcp.23.071","article-title":"Crosstalk mechanisms between glomerular endothelial cells and podocytes in renal diseases and kidney transplantation","volume":"43","author":"Li","year":"2024","journal-title":"Kidney Res Clin Pract"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.75","article-title":"Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis","volume":"75","author":"Avihingsanon","year":"2009","journal-title":"Kidney Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.21315\/mjms2017.24.5.7","article-title":"Serum vascular endothelial growth factor (VEGF) as a biomarker for disease activity in lupus nephritis","volume":"24","author":"Ghazali","year":"2017","journal-title":"Malays J Med Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2020.96617","article-title":"Renal involvement in systemic lupus erythematosus: additional histopathological lesions","volume":"19","author":"Muniz","year":"2023","journal-title":"Arch Med Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1053\/j.ackd.2019.08.009","article-title":"Membranous lupus nephritis: A clinical review","volume":"26","author":"Almaani","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000512278","article-title":"Lupus membranous nephropathy","volume":"1","author":"Ponticelli","year":"2021","journal-title":"Glomerular Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket491","article-title":"Podocyte involvement in lupus nephritis based on the 2003 ISN\/RPS system: a large cohort study from a single centre","volume":"53","author":"Wang","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/his.13454","article-title":"Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis","volume":"72","author":"Nawata","year":"2018","journal-title":"Histopathology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210391","article-title":"High systemic type I interferon activity is associated with active class III\/IV lupus nephritis","volume":"49","author":"Iwamoto","year":"2022","journal-title":"J Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.250","article-title":"Podocyte dysfunction in atypical haemolytic uraemic syndrome","volume":"11","author":"Noris","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"13074","DOI":"10.1038\/s41598-023-40346-8","article-title":"Mesenchymal stem cells enhance CCL8 expression by podocytes in lupus-prone MRL.Fas(lpr) mice","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2015.02.031","article-title":"Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1\u03b1 and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway","volume":"84","author":"Mashmoushi","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1159\/000491904","article-title":"Activation of cyclooxygenase-2 by ATF4 during endoplasmic reticulum stress regulates kidney podocyte autophagy induced by lupus nephritis","volume":"48","author":"Jin","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1006\/clin.1997.4332","article-title":"Effect of late modulation of nitric oxide production on murine lupus","volume":"83","author":"Oates","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e3181889e13","article-title":"Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL\/lpr mice deficient in the NOS2 gene","volume":"56","author":"Njoku","year":"2008","journal-title":"J Investig Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310397412","article-title":"Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology","volume":"20","author":"Perysinaki","year":"2011","journal-title":"Lupus"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw002","article-title":"Urinary dedifferentiated podocytes as a non-invasive biomarker of lupus nephritis","volume":"31","author":"Perez-Hernandez","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009080805","article-title":"Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis","volume":"21","author":"Yung","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013090987","article-title":"Glomerular autoimmune multicomponents of human lupus nephritis in vivo: \u03b1-enolase and annexin AI","volume":"25","author":"Bruschi","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12882-019-1482-z","article-title":"Urinary podocyte microparticles are associated with disease activity and renal injury in systemic lupus erythematosus","volume":"20","author":"Lu","year":"2019","journal-title":"BMC Nephrol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1159\/000547044","article-title":"Serum NF-\u03baB-regulated biomarkers of proliferative lupus nephritis","volume":"5","author":"Shoctor","year":"2025","journal-title":"Glomerular Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.15586\/aei.v53i3.1313","article-title":"Knockdown of TRIM22 regulates the expression of NF-\u03baB\/NLRP3 and alleviates inflammation and renal injury in mice with lupus nephritis","volume":"53","author":"Chen","year":"2025","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-017-0512-x","article-title":"UCH-L1 expressed by podocytes: a potentially therapeutic target for lupus nephritis","volume":"40","author":"Cui","year":"2017","journal-title":"Inflammation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"F1683","DOI":"10.1152\/ajprenal.00512.2017","article-title":"Podocytes contribute, and respond, to the inflammatory environment in lupus nephritis","volume":"315","author":"Wright","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316646861","article-title":"Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients","volume":"25","author":"Ma","year":"2016","journal-title":"Lupus"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00143.2010","article-title":"AlphaV-integrins mediate the mechanoprotective action of osteopontin in podocytes","volume":"300","author":"Schordan","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/art.41508","article-title":"Urinary biomarkers in lupus nephritis: are we there yet","volume":"73","author":"Mok","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.09.007","article-title":"Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts","volume":"106","author":"Vodehnal","year":"2024","journal-title":"Kidney Int"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001418","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond","volume":"12","author":"Barguil Macedo","year":"2025","journal-title":"Lupus Sci Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.5711","article-title":"Involvement of TWEAK and the NF-\u03baB signaling pathway in lupus nephritis","volume":"15","author":"Sun","year":"2018","journal-title":"Exp Ther Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s41927-020-00162-3","article-title":"Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis","volume":"4","author":"Gasparin","year":"2020","journal-title":"BMC Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13075-017-1498-3","article-title":"Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis","volume":"20","author":"Mok","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B67","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.2174\/1381612826666200826135929","article-title":"Elevated urinary and blood vascular cell adhesion molecule-1 as potential biomarkers for active systemic lupus erythematosus: A meta-analysis","volume":"26","author":"Xia","year":"2020","journal-title":"Curr Pharm Des"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22762","article-title":"Development of a novel renal activity index of lupus nephritis in children and young adults","volume":"68","author":"Brunner","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3892\/etm.2021.9752","article-title":"Knockout of NGAL aggravates tubulointerstitial injury in a mouse model of diabetic nephropathy by enhancing oxidative stress and fibrosis","volume":"21","author":"Liu","year":"2021","journal-title":"Exp Ther Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1042\/CS20171592","article-title":"More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases","volume":"132","author":"Buonafine","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.908158","article-title":"Neutrophil gelatinase-associated lipocalin attenuates ischemia\/reperfusion injury in an in vitro model via autophagy activation","volume":"24","author":"Yan","year":"2018","journal-title":"Med Sci Monit"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312451784","article-title":"Early treatment with glucocorticoids or cyclophosphamide retains the slit diaphragm proteins nephrin and podocin in experimental lupus nephritis","volume":"21","author":"Moysiadis","year":"2012","journal-title":"Lupus"},{"key":"B73","doi-asserted-by":"publisher","first-page":"32087","DOI":"10.1038\/srep32087","article-title":"Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models","volume":"6","author":"Shen","year":"2016","journal-title":"Sci Rep"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040591","article-title":"Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses","volume":"41","author":"Bossen","year":"2011","journal-title":"Eur J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191393","article-title":"Critical requirement for BCR, BAFF, and BAFFR in memory B cell survival","volume":"218","author":"M\u00fcller-Winkler","year":"2021","journal-title":"J Exp Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1604529113","article-title":"Canonical NF-\u03baB signaling is uniquely required for the long-term persistence of functional mature B cells","volume":"113","author":"Derudder","year":"2016","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2027516","article-title":"Belimumab as add-on therapy in lupus nephritis","volume":"383","author":"Ward","year":"2020","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"B83","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the east asian population","volume":"81","author":"Yu","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Roug\u00e9","year":"2020","journal-title":"Science"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1024068","article-title":"Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives","volume":"13","author":"Hartinger","year":"2022","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14240","article-title":"Efficacy and safety of an anti-CD20 monoclonal antibody, rituximab, for lupus nephritis: A meta-analysis","volume":"25","author":"Teng","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"Clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1432331","article-title":"Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus","volume":"28","author":"Ishii","year":"2018","journal-title":"Mod Rheumatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756941","article-title":"Clinical experience of proteasome inhibitor bortezomib regarding efficacy and safety in severe systemic lupus erythematosus: A nationwide study","volume":"12","author":"Walhelm","year":"2021","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.683249","article-title":"Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands(+) Macrophages via Activating IL-4\/STAT6\/PD-L2 Signaling","volume":"12","author":"Liang","year":"2021","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2016.10.498","article-title":"ROS-JNK1\/2-dependent activation of autophagy is required for the induction of anti-inflammatory effect of dihydroartemisinin in liver fibrosis","volume":"101","author":"Zhang","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1186\/s12967-025-06574-4","article-title":"Engineered macrophage membrane-coated dihydroartemisinin nanoparticles with enhanced CCR2 expression improved symptoms in MRL\/LPR mice by metabolic reprogramming of proinflammatory macrophages","volume":"23","author":"Zhao","year":"2025","journal-title":"J Transl Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"152965","DOI":"10.1016\/j.phymed.2019.152965","article-title":"Therapeutic effects of artesunate on lupus-prone MRL\/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway","volume":"62","author":"Dang","year":"2019","journal-title":"Phytomedicine"},{"key":"B110","doi-asserted-by":"publisher","first-page":"F769","DOI":"10.1152\/ajprenal.00649.2016","article-title":"(5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL\/lpr mice by preventing infiltration of immune cells","volume":"312","author":"Zhang","year":"2017","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1624850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T04:22:16Z","timestamp":1759983736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1624850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":110,"alternative-id":["10.3389\/fimmu.2025.1624850"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1624850","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"article-number":"1624850"}}